These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23183429)

  • 1. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.
    Kastritis E; Terpos E; Moulopoulos L; Spyropoulou-Vlachou M; Kanellias N; Eleftherakis-Papaiakovou E; Gkotzamanidou M; Migkou M; Gavriatopoulou M; Roussou M; Tasidou A; Dimopoulos MA
    Leukemia; 2013 Apr; 27(4):947-53. PubMed ID: 23183429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
    Kyrtsonis MC; Vassilakopoulos TP; Kafasi N; Sachanas S; Tzenou T; Papadogiannis A; Galanis Z; Kalpadakis C; Dimou M; Kyriakou E; Angelopoulou MK; Dimopoulou MN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Panayiotidis P; Pangalis GA
    Br J Haematol; 2007 May; 137(3):240-3. PubMed ID: 17408464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving use of serum free light chain assays in haematology.
    Pratt G
    Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
    Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
    BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.
    Hillengass J; Fechtner K; Weber MA; Bäuerle T; Ayyaz S; Heiss C; Hielscher T; Moehler TM; Egerer G; Neben K; Ho AD; Kauczor HU; Delorme S; Goldschmidt H
    J Clin Oncol; 2010 Mar; 28(9):1606-10. PubMed ID: 20177023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature.
    Siragusa S; Morice W; Gertz MA; Kyle RA; Greipp PR; Lust JA; Witzig TE; Lacy MQ; Zeldenrust SR; Rajkumar SV; Russell SJ; Hayman SR; Buadi F; Kumar SK; Dingli D; Dispenzieri A
    Ann Hematol; 2011 Jan; 90(1):101-6. PubMed ID: 20645101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biochemical and immunological findings of multiple myeloma].
    Asaoku H
    Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum free light chains for monitoring multiple myeloma.
    Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
    Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum free light chains for diagnosis and follow-up of multiple myeloma].
    Jung S; Kim M; Lim J; Kim Y; Han K; Min CK; Min WS
    Korean J Lab Med; 2008 Jun; 28(3):169-73. PubMed ID: 18594166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.
    Moulopoulos LA; Dimopoulos MA; Kastritis E; Christoulas D; Gkotzamanidou M; Roussou M; Koureas A; Migkou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Gika D; Koutoulidis V; Terpos E
    Am J Hematol; 2012 Sep; 87(9):861-4. PubMed ID: 22641455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
    Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G;
    Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance.
    Rajkumar SV; Kyle RA; Therneau TM; Clark RJ; Bradwell AR; Melton LJ; Larson DR; Plevak MF; Katzmann JA
    Br J Haematol; 2004 Nov; 127(3):308-10. PubMed ID: 15491291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
    Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
    Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
    Kyle RA; Rajkumar SV
    Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation.
    Hillengass J; Zechmann C; Bäuerle T; Wagner-Gund B; Heiss C; Benner A; Ho A; Neben K; Hose D; Kauczor HU; Goldschmidt H; Delorme S; Moehler T
    Clin Cancer Res; 2009 May; 15(9):3118-25. PubMed ID: 19366830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.
    Mai EK; Hielscher T; Kloth JK; Merz M; Shah S; Raab MS; Hillengass M; Wagner B; Jauch A; Hose D; Weber MA; Delorme S; Goldschmidt H; Hillengass J
    Haematologica; 2015 Jun; 100(6):818-25. PubMed ID: 25795721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
    Larsen JT; Kumar SK; Dispenzieri A; Kyle RA; Katzmann JA; Rajkumar SV
    Leukemia; 2013 Apr; 27(4):941-6. PubMed ID: 23183428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.
    Dispenzieri A; Kyle RA; Katzmann JA; Therneau TM; Larson D; Benson J; Clark RJ; Melton LJ; Gertz MA; Kumar SK; Fonseca R; Jelinek DF; Rajkumar SV
    Blood; 2008 Jan; 111(2):785-9. PubMed ID: 17942755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.